Kilitch Drugs (India) Ltd.

KILITCH

₹329.95

2.09% (6.75)

Market Cap

₹565 Cr.

P/E

20.49

Key Ratios

Edit Ratio's

Market cap

565 Cr

20.49

Prom Holding

63.77 %

ROE (%)

13.20

ROCE (%)

17.64

Div Yield (%)

Sales

209 Cr

OPM (%)

15.10 %

Debt to Equity

0.24

Edit Ratio's

About

Kilitch Drugs (India) Limited is a Mumbai-based pharmaceutical company specializing in manufac… Read more

Low

265

52W Range

High

490

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a good pace
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Share price

Share price has increased over last 10 years but more due to rerating
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Customers

Abbott India Ltd.
Ajanta Pharma Ltd.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd.
Procter & Gamble Health Ltd.
Novartis India Ltd.
Unichem Laboratories Ltd.
Zydus Wellness Ltd.
AvaCare Health
Fusion Health Care Pvt. Ltd.
Indoco Remedies Ltd.
Mankind Pharma
Shalina Healthcare

Showing 5 of 13

FAQs on Kilitch Drugs (India) Ltd. Business

What does Kilitch Drugs(India) do?

Kilitch Drugs (India) Limited, based in Mumbai, is a pharmaceutical company focusing on manufacturing and marketing antibacterial parenteral formulations including Carbapenems, Cephalosporins, and anti malarials. It transferred some products to Akorn India Pvt. Ltd. in 2012.

Who are the competitors of Kilitch Drugs(India)?

Kilitch Drugs(India) major competitors are Shivalik Rasayan, Prevest Denpro, Medicamen Biotech, Jenburkt Pharma, Medico Remedies, Bharat Parenterals, Albert David.
Market Cap of Kilitch Drugs(India) is ₹600 Crs.
While the median market cap of its peers are ₹518 Crs.

Is Kilitch Drugs(India) financially stable compared to its competitors?

Kilitch Drugs(India) seems to be less financially stable compared to its competitors.
Altman Z score of Kilitch Drugs(India) is 5.37 and is ranked 5 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Companies Doing Major Expansion

Companies in any sector undergoing sizeable expansion

Run Query

Superstar Favourites

Companies where superstar investors like Rakesh Jhunjhunwala, Asish Kacholia have invested

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May Nov	Dec	Mar				Mar	Jun Sep
Investor Presentation
Conference Call		Mar	Mar
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Pharmaceuticals

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Kilitch Drugs (India) Ltd.

Kilitch Drugs (India) Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

8 Yes

2 Neutral

7 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Promoter Holding

Depreciation Effect

Retail Holding

Revenue Recognition

Price & Performance

Capex vs ROCE

ROE

Working Capital

Debt

Sales Growth

Balance Sheet Strength

Current vs Historic Valuation

Share price

Margin Stability

ROCE Strength

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Peer Comparison

Corporate Actions

Customers

FAQs on Kilitch Drugs (India) Ltd. Business

What does Kilitch Drugs(India) do?

Who are the competitors of Kilitch Drugs(India)?

Is Kilitch Drugs(India) financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE